ParkinsonFranceV1, PascalFrancis, Curation, bibRecord, 000291

Levodopa: Is toxicity a myth?

Identifieur interne : 000291 ( PascalFrancis/Curation ); précédent : 000290; suivant : 000292

Levodopa: Is toxicity a myth?

Auteurs : Y. Agid [France]

Source :

Neurology [ 0028-3878 ] ; 2001.

RBID : Pascal:02-0185321

Descripteurs français

Pascal (Inist)
- Lévodopa, Chimiothérapie, Antiparkinsonien, Parkinson maladie, Neurone catécholaminergique, Noyau gris central, Long terme, Traitement, Toxicité, Homme, Animal.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Animal, Antiparkinson agent, Basal ganglion, Catecholaminergic neuron, Chemotherapy, Human, Levodopa, Long term, Parkinson disease, Toxicity, Treatment.

Abstract

Article abstract-Whether a drug such as levodopa, which is prescribed for long periods, may be toxic is a legitimate and even indispensable question. The problem is no different from that posed by other drugs-such as calcium antagonists, antihypertensives, or hormones-normally prescribed for chronic diseases. What, however, is meant in this context by "toxic" (from the Greek toxicon, meaning poison) Irrevocable damage such as cell loss should not be confused with reversible side effects resulting from cell dysfunction. Clinically or experimentally, levodopa has not been shown to accelerate neurodegeneration or cause permanent impairment of cell function in a manner that would result in irreversible side effects. These data have been reasonably well established in vivo in animals and humans, although preliminary studies suggesting that levodopa is a trophic factor remain unconfirmed. Like oxygen or calcium, levodopa can be toxic in vitro when it is present in high concentrations or in the absence of glial cells. However, glial cells are much more numerous than neurons in vivo, so these conditions cannot simply be extrapolated to three-dimensional brain structures in which protective interactions with the cellular environment abound. Because levodopa remains the most effective treatment available for Parkinson's disease, questions regarding timing or manner of administration of the drug should arise not because levodopa is toxic to nerve cells, but because it causes reversible side effects. When the elementary rules of substitutive therapy to provide maximum comfort while limiting side effects are followed, we need not fear that levodopa is dangerous unless the contrary is proven.

A01	`01`	`1`		`@0 0028-3878`
A02	`01`			`@0 NEURAI`
A03		`1`		`@0 Neurology`
A05				`@2 57`
A06				`@2 10 @3 SUP3`
A08	`01`	`1`	`ENG`	`@1 Levodopa: Is toxicity a myth?`
A09	`01`	`1`	`ENG`	`@1 50th anniversary reprint collection: Parkinson's disease`
A11	`01`	`1`		`@1 AGID (Y.)`
A12	`01`	`1`		`@1 JANKOVIC (Joseph) @9 ed.`
A14	`01`			`@1 Fédération de Neurologie and INSERM U289, Hôpital de la Salpetrière @2 Paris @3 FRA @Z 1 aut.`
A15	`01`			`@1 Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine @2 Houston, TX 77030 @3 USA @Z 1 aut.`
A20				`@2 S46-S51`
A21				`@1 2001`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 6345 @5 354000100284550060`
A44				`@0 0000 @1 © 2002 INIST-CNRS. All rights reserved.`
A45				`@0 50 ref.`
A47	`01`	`1`		`@0 02-0185321`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Neurology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Article abstract-Whether a drug such as levodopa, which is prescribed for long periods, may be toxic is a legitimate and even indispensable question. The problem is no different from that posed by other drugs-such as calcium antagonists, antihypertensives, or hormones-normally prescribed for chronic diseases. What, however, is meant in this context by "toxic" (from the Greek toxicon, meaning poison) Irrevocable damage such as cell loss should not be confused with reversible side effects resulting from cell dysfunction. Clinically or experimentally, levodopa has not been shown to accelerate neurodegeneration or cause permanent impairment of cell function in a manner that would result in irreversible side effects. These data have been reasonably well established in vivo in animals and humans, although preliminary studies suggesting that levodopa is a trophic factor remain unconfirmed. Like oxygen or calcium, levodopa can be toxic in vitro when it is present in high concentrations or in the absence of glial cells. However, glial cells are much more numerous than neurons in vivo, so these conditions cannot simply be extrapolated to three-dimensional brain structures in which protective interactions with the cellular environment abound. Because levodopa remains the most effective treatment available for Parkinson's disease, questions regarding timing or manner of administration of the drug should arise not because levodopa is toxic to nerve cells, but because it causes reversible side effects. When the elementary rules of substitutive therapy to provide maximum comfort while limiting side effects are followed, we need not fear that levodopa is dangerous unless the contrary is proven.
C02	`01`	`X`		`@0 002B02U01`
C03	`01`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 01`
C03	`01`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 01`
C03	`01`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 01`
C03	`02`	`X`	`FRE`	`@0 Chimiothérapie @5 02`
C03	`02`	`X`	`ENG`	`@0 Chemotherapy @5 02`
C03	`02`	`X`	`SPA`	`@0 Quimioterapia @5 02`
C03	`03`	`X`	`FRE`	`@0 Antiparkinsonien @5 03`
C03	`03`	`X`	`ENG`	`@0 Antiparkinson agent @5 03`
C03	`03`	`X`	`SPA`	`@0 Antiparkinsoniano @5 03`
C03	`04`	`X`	`FRE`	`@0 Parkinson maladie @5 04`
C03	`04`	`X`	`ENG`	`@0 Parkinson disease @5 04`
C03	`04`	`X`	`SPA`	`@0 Parkinson enfermedad @5 04`
C03	`05`	`X`	`FRE`	`@0 Neurone catécholaminergique @5 07`
C03	`05`	`X`	`ENG`	`@0 Catecholaminergic neuron @5 07`
C03	`05`	`X`	`SPA`	`@0 Neurona catecolaminérgica @5 07`
C03	`06`	`X`	`FRE`	`@0 Noyau gris central @5 10`
C03	`06`	`X`	`ENG`	`@0 Basal ganglion @5 10`
C03	`06`	`X`	`SPA`	`@0 Núcleo basal @5 10`
C03	`07`	`X`	`FRE`	`@0 Long terme @5 13`
C03	`07`	`X`	`ENG`	`@0 Long term @5 13`
C03	`07`	`X`	`SPA`	`@0 Largo plazo @5 13`
C03	`08`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`08`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`08`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`09`	`X`	`FRE`	`@0 Toxicité @5 18`
C03	`09`	`X`	`ENG`	`@0 Toxicity @5 18`
C03	`09`	`X`	`SPA`	`@0 Toxicidad @5 18`
C03	`10`	`X`	`FRE`	`@0 Homme @5 20`
C03	`10`	`X`	`ENG`	`@0 Human @5 20`
C03	`10`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`11`	`X`	`FRE`	`@0 Animal @5 21`
C03	`11`	`X`	`ENG`	`@0 Animal @5 21`
C03	`11`	`X`	`SPA`	`@0 Animal @5 21`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 45`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 45`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 45`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 46`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 46`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 46`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 47`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 47`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 47`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 48`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 48`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 48`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 49`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 49`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 49`
N21				`@1 105`
N82				`@1 PSI`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001145

Links to Exploration step

Pascal:02-0185321

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Levodopa: Is toxicity a myth?</title>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Y. Agid</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Fédération de Neurologie and INSERM U289, Hôpital de la Salpetrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">02-0185321</idno>
<date when="2001">2001</date>
<idno type="stanalyst">PASCAL 02-0185321 INIST</idno>
<idno type="RBID">Pascal:02-0185321</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001145</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000291</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Levodopa: Is toxicity a myth?</title>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Y. Agid</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Fédération de Neurologie and INSERM U289, Hôpital de la Salpetrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
<imprint><date when="2001">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term>
<term>Antiparkinson agent</term>
<term>Basal ganglion</term>
<term>Catecholaminergic neuron</term>
<term>Chemotherapy</term>
<term>Human</term>
<term>Levodopa</term>
<term>Long term</term>
<term>Parkinson disease</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Lévodopa</term>
<term>Chimiothérapie</term>
<term>Antiparkinsonien</term>
<term>Parkinson maladie</term>
<term>Neurone catécholaminergique</term>
<term>Noyau gris central</term>
<term>Long terme</term>
<term>Traitement</term>
<term>Toxicité</term>
<term>Homme</term>
<term>Animal</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Article abstract-Whether a drug such as levodopa, which is prescribed for long periods, may be toxic is a legitimate and even indispensable question. The problem is no different from that posed by other drugs-such as calcium antagonists, antihypertensives, or hormones-normally prescribed for chronic diseases. What, however, is meant in this context by "toxic" (from the Greek toxicon, meaning poison) Irrevocable damage such as cell loss should not be confused with reversible side effects resulting from cell dysfunction. Clinically or experimentally, levodopa has not been shown to accelerate neurodegeneration or cause permanent impairment of cell function in a manner that would result in irreversible side effects. These data have been reasonably well established in vivo in animals and humans, although preliminary studies suggesting that levodopa is a trophic factor remain unconfirmed. Like oxygen or calcium, levodopa can be toxic in vitro when it is present in high concentrations or in the absence of glial cells. However, glial cells are much more numerous than neurons in vivo, so these conditions cannot simply be extrapolated to three-dimensional brain structures in which protective interactions with the cellular environment abound. Because levodopa remains the most effective treatment available for Parkinson's disease, questions regarding timing or manner of administration of the drug should arise not because levodopa is toxic to nerve cells, but because it causes reversible side effects. When the elementary rules of substitutive therapy to provide maximum comfort while limiting side effects are followed, we need not fear that levodopa is dangerous unless the contrary is proven.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0028-3878</s0>
</fA01>
<fA02 i1="01"><s0>NEURAI</s0>
</fA02>
<fA03 i2="1"><s0>Neurology</s0>
</fA03>
<fA05><s2>57</s2>
</fA05>
<fA06><s2>10</s2>
<s3>SUP3</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Levodopa: Is toxicity a myth?</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>50th anniversary reprint collection: Parkinson's disease</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>AGID (Y.)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>JANKOVIC (Joseph)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>Fédération de Neurologie and INSERM U289, Hôpital de la Salpetrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine</s1>
<s2>Houston, TX 77030</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA20><s2>S46-S51</s2>
</fA20>
<fA21><s1>2001</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>6345</s2>
<s5>354000100284550060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2002 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>50 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>02-0185321</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Neurology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Article abstract-Whether a drug such as levodopa, which is prescribed for long periods, may be toxic is a legitimate and even indispensable question. The problem is no different from that posed by other drugs-such as calcium antagonists, antihypertensives, or hormones-normally prescribed for chronic diseases. What, however, is meant in this context by "toxic" (from the Greek toxicon, meaning poison) Irrevocable damage such as cell loss should not be confused with reversible side effects resulting from cell dysfunction. Clinically or experimentally, levodopa has not been shown to accelerate neurodegeneration or cause permanent impairment of cell function in a manner that would result in irreversible side effects. These data have been reasonably well established in vivo in animals and humans, although preliminary studies suggesting that levodopa is a trophic factor remain unconfirmed. Like oxygen or calcium, levodopa can be toxic in vitro when it is present in high concentrations or in the absence of glial cells. However, glial cells are much more numerous than neurons in vivo, so these conditions cannot simply be extrapolated to three-dimensional brain structures in which protective interactions with the cellular environment abound. Because levodopa remains the most effective treatment available for Parkinson's disease, questions regarding timing or manner of administration of the drug should arise not because levodopa is toxic to nerve cells, but because it causes reversible side effects. When the elementary rules of substitutive therapy to provide maximum comfort while limiting side effects are followed, we need not fear that levodopa is dangerous unless the contrary is proven.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02U01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Neurone catécholaminergique</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Catecholaminergic neuron</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Neurona catecolaminérgica</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Noyau gris central</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Basal ganglion</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Núcleo basal</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Long terme</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Long term</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Largo plazo</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Animal</s0>
<s5>21</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Animal</s0>
<s5>21</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Animal</s0>
<s5>21</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>45</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>45</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>45</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>46</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>46</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>46</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>47</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>47</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>47</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>48</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>48</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>48</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>49</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>49</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>49</s5>
</fC07>
<fN21><s1>105</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000291 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000291 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:02-0185321
   |texte=   Levodopa: Is toxicity a myth?
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Levodopa: Is toxicity a myth?

Levodopa: Is toxicity a myth?

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri